GLOW is a multi peptide research blend containing GHK Cu, BPC 157, and TB 500, formulated for studies of regenerative and cellular signaling biology in controlled in vitro and preclinical models
Have your alcohol swabs, sterile syringes, peptide vial, and BAC water vial all laid out
Contribute to heart health by potentially reducing the risk of cardiovascular diseases, although the evidence here remains mixed and requires further research
Avoid injecting into areas with visible veins, scars, or irritations
Sikiric is named on BPC-157-related patent applications dating back to at least 1989, and Croatian government records list Predrag Sikiric as an owner of PharmaCotherapia, the company that sponsored the Tijuana trial